| http://www.w3.org/ns/prov#value | - en to patients with other types of cancers.This is a Phase II trialwhat is involved:Participants will be randomly assigned to 1 or 2 groups and will receive one of the following treatments: Everolimus/Afinitor (mTOR inhibitor), Trametinib DMSO (MEK inhibitor), Temozolomide and ABT-888 (PARP inhibitor), or Carboplatin and MK-1775 (Wee1 inhibitor)Group 1: ExperimentalReceive a treatment corresponding
|
